8 Den relative risiko for venøse tromboemboliske tilfælde, som er observeret under raloxifenbehandling, var 1, 60 (konfidensinterval 0, 95- 2, 71) i forhold til placebo og 1, 0 (konfidensinterval 0, 3- 6, 2) i forhold til østrogen eller hormonal substitutionsterapi.
8 The relative risk of venous thromboembolic events observed during raloxifene treatment was 1.60 (CI 0.95, 2.71) when compared to placebo, and was 1.0 (CI 0.3, 6.2) when compared to oestrogen or hormonal replacement therapy.